About Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia is a malignant condition characterized by increased production of lymphocytes. It has been observed that the cancer first affects B-lymphocytes and then it can spread to other parts of the body. This leukemia is diagnosed mostly at later stages because of the slow buildup of the cancerous cells. During the course of the disease, the malignancy spreads to the spleen, liver, and lymph nodes. The course of the disease is heterogeneous, and prognosis is difficult. Symptoms include swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Chronic lymphocytic leukemia can be treated with radiation, steroids, chemotherapy, targeted therapy, transplants (bone marrow, stem cell), and surgical procedure to remove the spleen (splenectomy).
Technavio's analysts forecast the global chronic lymphocytic leukemia therapeutics market to grow at a CAGR of 18.52% over the period 2014-2019.
Covered in this Report
In this report, Technavio covers the present scenario and growth prospects of the global chronic lymphocytic leukemia therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used in the treatment of chronic lymphocytic leukemia.
Based on the type of molecule, we group the market into two categories:
• Biologics
• Small molecules
Based on the route of administration, we group the market into two:
• Oral
• Parenteral
This report includes a discussion of the market in the following three regions:
• Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
• EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle
Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
• APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is a major untapped market with many leading vendors in the global chronic lymphocytic leukemia therapeutics market.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers and challenges, as well as the key trends.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• F. Hoffmann-La Roche
• Novartis
• Teva Pharmaceutical Industries
Other Prominent Vendors
• Actavis
• Amgen
• Aryogen
• Astellas
• Bristol-Myers Squibb
• Eagle Pharmaceuticals
• Eisai
• Fresenius Kabi
• Genmab
• Gilead Sciences
• H. Lundbeck
• Hospira
• idd biotech
• Immunomedics
• Johnson & Johnson
• Mundipharma
• Mylan
• Noxxon
• Ono Pharmaceutical
• PDL BioPharma
• Pfizer
• Pharmacyclics
• Regeneron
• Sagent Pharmaceutical
• Sanofi
• SymBio Pharmaceuticals
• TheraMAB
Key Market Driver
• Increase in Patient Pool
• For a full, detailed list, view our report
Key Market Challenge
• Unknown Disease Etiology
• For a full, detailed list, view our report
Key Market Trend
• Strategic Alliances
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Gazyva/Gazyvaro
04.1.2 MabThera/Rituxan
04.1.3 Arzerra
04.1.4 Treanda
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Disease Overview
06.1 Understanding the Disease
06.2 Types of Chronic Lymphocytic Leukemia
06.3 Symptoms
06.4 Diagnosis
06.5 Staging
06.6 Epidemiology
06.7 Management
06.8 Economic Burden
07. Introduction
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Pipeline Portfolio
09.1 Key Information on the Major Pipeline Molecules
09.1.1 RG 105 SC Formulation
09.1.2 Obinutuzumab/ Venetoclax
09.1.3 RG 7596 (Polatuzumab vedotin)
09.1.4 RG 7601 (Venetoclax)
10. Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral
11. Market Segmentation by Type of Molecule
11.1 Small Molecules
11.2 Biologics
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 F. Hoffmann-La Roche
20.2.2 Teva Pharmaceutical Industries
20.2.3 Novartis
20.3 Other and Future Prominent Vendors
21. Key Vendor Analysis
21.1 F. Hoffmann-La Roche
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation
21.1.4 Business Segmentation by Revenue 2012 and 2013
21.1.5 Sales by Geography
21.1.6 Business Strategy
21.1.7 Key Information
21.1.8 SWOT Analysis
21.2 Novartis
21.2.1 Key Facts
21.2.2 Business Description
21.2.3 Business Segmentation
21.2.4 Revenue by Business Segmentation
21.2.5 Revenue Comparison 2012 and 2013
21.2.6 Sales by Geography
21.2.7 Business Strategy
21.2.8 Key Developments
21.2.9 SWOT Analysis
21.3 Teva Pharmaceutical Industries
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation
21.3.4 Revenue by Business Segmentation
21.3.5 Revenue Comparison 2012 and 2013
21.3.6 Revenue Segmentation by Geography
21.3.7 Business Strategy
21.3.8 Key Developments
21.3.9 SWOT Analysis
22. Other Reports in this Series
List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of Chronic Lymphocytic Leukemia
Exhibit 3: Type of Chronic Lymphocytic Leukemia
Exhibit 4: Major Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
Exhibit 5: Other Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
Exhibit 6: Rai Staging of Chronic Lymphocytic Leukemia
Exhibit 7: Binet Staging of Chronic Lymphocytic Leukemia
Exhibit 8: Management of Chronic Lymphocytic Leukemia
Exhibit 9: Economic Burden of Chronic Lymphocytic Leukemia
Exhibit 10: Global Chronic Lymphocytic Leukemia Therapeutics Market 2014-2019 ($ millions)
Exhibit 11: Key Takeaways: Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 12: Drug Candidates by Stage of Development, in percentage
Exhibit 13: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Route of Administration
Exhibit 14: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Type of Molecules
Exhibit 15: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Geography, 2014
Exhibit 16: Drivers of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 17: Challenges of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 18: Trends of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 19: Global Sales and YoY Growth Rate of Rituxan/MabThera 2010-2014 ($ millions)
Exhibit 20: Global Sales and YoY Growth Rate of Treanda 2010-2014 ($ millions)
Exhibit 21: Global Sales and YoY Growth Rate of Arzerra 2010-2014($ millions)
Exhibit 22: Sales and YoY Growth Rate of Arzerra in US 2010-2014 ($ millions)
Exhibit 23: Sales and YoY Growth Rate of Arzerra in Europe 2010-2014 ($ millions)
Exhibit 24: Region-wise Revenue Comparison of Arzerra 2010-2014 ($ millions)
Exhibit 25: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 26: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 27: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 28: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 29: Novartis AG: Business Segmentation
Exhibit 30: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 31: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 32: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 33: Teva Pharmaceutical Industries Ltd.: Business Segmentation
Exhibit 34: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2013
Exhibit 35: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 36: Teva Pharmaceutical Industries Ltd.: Revenue by Geographical Segmentation 2013
